October 2021 | AIChE

You are here

October 2021

Kelly Stevens

Kelly Stevens is an Assistant Professor in the Departments of Bioengineering and Pathology at the University of Washington. Kelly received a B.S. in Biomedical Engineering from the University of Wisconsin-Madison, a Ph.D. in Bioengineering from the University of Washington, and postdoctoral training at Massachusetts Institute of Technology. Her work bridges several facets of regenerative medicine, including pluripotent stem cell biology, transplantation, tissue engineering, and micro/nanofabrication. In particular, she has made several seminal contributions in the development of complex...Read more

Denise Kelly

Professor Denise Kelly joined Seventure Partners, a European Leader in Venture Capital, in 2015 as an Investment Advisor to the Life Sciences Team and is focused specifically, on Human Microbiome investment opportunities across Europe and the USA.

Prior to joining Seventure, Denise was Head of her Research team at the World-renowned Rowett Institute, University of Aberdeen, where she acquired over 20 years experience in gut microbiology and immunology. She was the (former) Founder Director, CEO and CSO of GT Biologics Ltd, one of the first translational spinouts, developing...Read more

Matthew Henn

Matthew Henn is the Executive Vice President and Chief Scientific Officer of Seres. He has over 20 years of combined research experience in microbial ecology, genomics and bioinformatics that spans both environmental and human disease applications. He has been involved in the discovery and clinical development of multiple microbiome therapeutics and has authored over 65 peer-reviewed publications. His research has focused on microbial physiology and the functional role of microbes in both environmental and human disease applications, and on the development of genomic and functional tools...Read more

Will DeLoache

Dr. DeLoache is Co-Founder and Chief Scientific Officer of Novome Biotechnologies, a biotechnology company based in South San Francisco that is engineering bacterial therapeutics for chronic diseases. Until 2019, he served as President and CEO of the company, helping to raise a combined $40M in financing. Prior to Novome, he worked as a Scientist at Zymergen, where he led the development of the company’s next-generation sequencing pipeline. Dr. DeLoache earned his Ph.D. in Bioengineering at the University of California, Berkeley, studying synthetic biology and metabolic engineering in the...Read more

Pages